PDCD1 and cancer: Monoclonal antibodies approved by the U.S. Food and Drug Administration (FDA) for cancer treatment include the programmed cell death 1 (PD-1) inhibitors nivolumab, pembrolizumab, cemiplimab, and dostarlimab and the programmed death ligand 1 (PD-L1) inhibitors atezolizumab, durvalumab, and avelumab [6].